PGEN: Intrexon Price to Sales
Precigen, Inc. (PGEN) focuses on developing UltraVector for oncology therapy while awaiting an FDA verdict on PRGN-2012. The P/S ratio history demonstrates the market valuation of the business, where 10.60 is the current value of the metric. The company's innovations enable the synthesis of modified cells directly within clinics, accelerating treatment. Meanwhile, the localization of development in the US minimizes geopolitical risks.
Analytical breakdowns for Intrexon (PGEN)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
- earnings and valuation multiples indicators:
PGEN - Company Net Income|Net Profit Forecast Precigen, Inc.|PGEN - Price to Earnings Ratio|Future Price to Earnings Multiple Precigen Inc|PGEN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Intrexon|PGEN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Precigen|PGEN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months precigen.com|PGEN - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Precigen, Inc.
- total revenue and sales volume data:
General company analysis:PGEN, precigen.com
To determine the long-term sustainability of Precigen, Inc. (PGEN), it is critical to correlate market capitalization with generated revenue, which allows for the real-time assessment of the business's fundamental value. By analyzing the revenue multiple, an investor evaluates the efficiency of asset monetization amid active liquidity spending on clinical trials and gene therapy R&D.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Sales Ratio PTGX|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|kiniksa.com - Market Capitalization-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|Price to Sales Adaptive Biotech ADPT|P/S Multiple CLDX|Market Cap to Revenue Aurinia Corp AUPH|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|Dianthus Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Multiple Pharvaris NV (PHVS)|ABCL: P/S Multiple|Price to Sales Tourmaline (TRML)|Price-to-Revenue Ratio Pharming Group N.V.|Market Cap to Revenue Ratio NKTR (nektar.com)|Market Cap to Revenue UPB (Upstream Bio)|ZBIO (Zenas Bio) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMNM (Immunome Corp)|Price-to-Revenue Coefficient Gossamer Bio Corp. (GOSS)|KALV - Price-to-Revenue Ratio|SEPN (septerna.com) - Market Cap to Revenue Ratio|PVLA: P/S Multiple|Market Cap to Revenue Savara Inc|Market Cap to Revenue RIGL|AnaptysBio Inc. (ANAB) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN: Price-to-Sales Ratio|P/S Multiple RAPT (RAPT Therapeutics)|Price-to-Revenue Multiple Aerovate Therapeutics, Inc.|Aclaris - P/S Multiple|Price to Sales Kyverna Therapeutics, Inc|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CABA|Price-to-Revenue Ratio Ventyx Biosciences, Inc.|Theratechnologies, Inc. - Price-to-Sales Ratio|P/S Multiple AVTX|ELDN (Eledon Pharmaceuticals, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple AGEN (Agenus)|P/S Multiple climbbio.com CLYM|ZURA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ATYR (aTyr Pharma Inc)|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ikena Oncology|STTK (Shattuck Labs Inc) - P/S Multiple|P/S Multiple Equillium Bio|Market Cap to Revenue CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ATRA (Atara Bio)|Price-to-Revenue Coefficient InflaRx NV (IFRX)|XFOR - Price-to-Revenue Ratio|Adicet Bio (ACET) - Market Cap to Revenue|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|Market Cap to Revenue BRNS|P/S Multiple Kezar Life Sciences Inc|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|akaritx.com - Market Cap to Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Price to Sales|GOVX - Price-to-Revenue Ratio|Price-to-Sales Ratio EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Carisma Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Price to Sales Bolt Bio BOLT|P/S Multiple HCWB|Market Cap to Revenue aptevotherapeutics.com APVO|P/S Multiple AIM (AIM ImmunoTech Inc.)|Price-to-Revenue Coefficient Aditxt Inc. (ADTX)|GRI Bio - P/S Multiple|Price-to-Revenue Multiple XORTX Therapeutics Inc (XRTX)|HIND: P/S Multiple|Price to Sales Revelation Biosciences Corp (REVB)|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|Market Cap to Revenue CALI (CalciMedica, Inc.)|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGMS - Price-to-Revenue Ratio|ITOS (iteostherapeutics.com) - Market Cap to Revenue Ratio|OCEA: P/S Multiple|Market Cap to Revenue TC BioPharm (Holdings) Plc|Market Cap to Revenue THRD
